Skip to main content

Market Overview

Citi Asks: Is A Mylan-Perrigo Merger Smart?

Share:

Citi issued an industry update after reports that Mylan NV (NASDAQ: MYL) proposed to acquire Perrigo Company (NYSE: PRGO) for $205 per share. Citi rates Mylan as Neutral with a $54 target price.

Analysts Liav Abraham and Timothy Li wrote, "Mylan has indicated its intent to continue to pursue inorganic growth, though a potential Mylan-Perrigo combination is not obviously strategic to us given Mylan's lack of presence in the OTC space....however we note that an acquisition of PRGO would afford Mylan diversification away from EpiPen, a higher organic growth profile, and EPS accretion."

Related Link: And The Winner From The Mylan-Perrigo Merger Is... Teva?

Citi notes that while it is unclear whether Mylan's bid for Perrigo will go hostile, under the Irish Takeover Code, companies exposed to hostile takeovers are unable to adopt poison pills. Value on the deal will most likely depend on the level of synergy capture, which is likely to be limited to Perrigo's Pharmaceutical business.

Latest Ratings for MYL

DateFirmActionFromTo
Oct 2020Wells FargoMaintainsEqual-Weight
Aug 2020UBSMaintainsNeutral
May 2020UBSMaintainsNeutral

View More Analyst Ratings for MYL

View the Latest Analyst Ratings

 

Related Articles (MYL)

View Comments and Join the Discussion!

Posted-In: Citi Liav Abraham Timothy LiAnalyst Color Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com